Trial Profile
Phase II study of the combination of PTK787/ZK222584 [vatalanib] and letrozole in postmenopausal women with advanced hormone receptor positive breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Vatalanib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 06 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 16 Aug 2006 New trial record.